Ra Pharmaceuticals, a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for complement-mediated diseases, recently announced interim results from their ongoing, global Phase 2 study evaluating RA101495 for the treatment of PNH. The press release announcing these results can be read here.
According to the news release, the results support the potential for RA101495 to be a safe, effective, and convenient subcutaneous, self-administered therapeutic option that PNH patients may readily adopt.
The Phase 2 study has a site in Toronto, Canada, but is no longer enrolling new patients. Ra Pharmaceuticals plans to enroll Canadian patients in the upcoming Phase 3 study, and hopes to have more sites involved. When enrollment opens, PNH Canada will send an update to the Canadian PNH community so that you can get involved. For more information on the ongoing study, please visit clinicaltrials.gov.